Keck School of Medicine of USC

Keck School of Medicine of USC

We are dedicated to promoting health, preventing and curing disease, advancing biomedical research and educating tomorrow’s physicians and scientists.

 

8th Annual USC Multi-Disciplinary Breast Cancer Symposium
05:35

8th Annual USC Multidisciplinary Breast Cancer Symposium

HR+HER2- High-Risk eBC: Surveying Efficacy Data of CDK4/6i in the Adjuvant Setting

FEATURING George Sledge
  • 186 views
  • February 22, 2021
09:19

8th Annual USC Multidisciplinary Breast Cancer Symposium

HR+/HER2- MBC: Outcomes of 1/2L CDK4/6 Inhibition

FEATURING George Sledge
  • 266 views
  • February 9, 2021
09:50

8th Annual USC Multidisciplinary Breast Cancer Symposium

ER+ Early Stage BC: Which Patients Should Avoid Chemotherapy? Does Chemo Add Benefit for Postmenopausal Women?

FEATURING George Sledge
  • 204 views
  • February 9, 2021
  • 1
06:22

8th Annual USC Multidisciplinary Breast Cancer Symposium

PI3K/AKT/mTOR Inhibition in Advanced BC: Is There Any Benefit With Alpelisib, Capivasertib, and Everolimus?

FEATURING George Sledge
  • 63 views
  • February 9, 2021
30:59

8th Annual USC Multidisciplinary Breast Cancer Symposium

Genetic Risk in BC: BRCA1/2 Mutations, Genetic Testing, Preventive Bilateral Mastectomy/Salpingo-Oophorectomy, Chemoprevention, NGS, Hereditary Syndromes

FEATURING Banu Arun
  • 17 views
  • February 9, 2021
35:08

8th Annual USC Multidisciplinary Breast Cancer Symposium

Oncoplastic Surgery and BC: What Is Extreme Oncoplasty? When Can We Use It?

FEATURING Melvin Silverstein
  • 46 views
  • February 9, 2021
  • 2
28:38

8th Annual USC Multidisciplinary Breast Cancer Symposium

Diagnostic MRI for Newly Diagnosed BC: Factors of Occult Lesions Detection, Predicting of pCR After Neoadjuvant Chemo, RFS After Neoadjuvant Chemo

FEATURING Stephen Sener
  • 474 views
  • February 9, 2021
  • 1
39:07

8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Challenges in HER2+ BC Testing: IHC Guidelines, Biomarker Testing for Targeted Therapy Selection, FISH Gene Assessment/Testing

FEATURING Michael Press
  • 52 views
  • February 9, 2021
18:27

8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Updates on HER2+ MBC: What Does the New Data on T-DXd Suggest? Do Neratinib-Based Regimens Improve Outcomes in CNS Metastases? Is There a Clinical Benefit of Retreating Pts With Pertuzumab?

FEATURING William Gradishar
  • 426 views
  • February 5, 2021
  • 2
11:34

8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Updates on HER2+ MBC: Tucatinib Combo and HRQoL in Brain Mets, Margetuximab+Chemo vs. Tras+Chemo, Subcutaneous Formulations

FEATURING William Gradishar
  • 113 views
  • February 5, 2021
  • 1
19:06

8th Annual USC Multidisciplinary Breast Cancer Symposium

USC Update on 1L Chemo Combination for Advanced TNBC: Does the Addition of Atezolizumab or Pembrolizumab Make a Difference?

FEATURING Sara A. Hurvitz
  • 138 views
  • January 28, 2021
06:31

8th Annual USC Multidisciplinary Breast Cancer Symposium

Innovations in Management of mTNBC: PARP Inhibitors

FEATURING Sara A. Hurvitz
  • 358 views
  • January 28, 2021
  • 3
13:11

8th Annual USC Multidisciplinary Breast Cancer Symposium

Clinical Trial Data on ADCs in TNBC: Sacituzumab Govitecan Efficacy & Biomarkers Analysis, T-DXd, Ladiratuzumab Vedotin

FEATURING Sara A. Hurvitz
  • 241 views
  • January 28, 2021
  • 2